Rubicon Research Limited Earnings Summary — Q1 FY2027
Rubicon Research Delivers Robust Q1 Performance with 52% Revenue Growth and Inorganic Expansion
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 5 consecutive quarters.
- Revenue of ₹534 Cr is 51.6% higher year-on-year.
- Revenue has compounded at 40.1% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹85 Cr is 95.8% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 67.2% annualised across the period.
- Operating margin stands at 24.2% in Q1 FY2027.
- Operating margin expanded by 171 bps year-on-year.
- PBT margin is 20.7%.
- Expense growth of 48.2% remained below revenue growth of 51.6%.
- Operating profit of ₹129 Cr is 63.2% higher year-on-year.
- Operating leverage continues to improve.
- 4 of the last 4 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 82/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2019 | Q4 FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 534 | 514 | 476 | 412 | 352 | 358 | 313 | 296 | — | — |
| Expenses | Improving | 405 | 395 | 367 | 318 | 273 | 286 | 244 | 234 | — | — |
| Operating Profit | Improving | 129 | 119 | 108 | 94 | 79 | 72 | 70 | 62 | — | — |
| Operating Margin | Stable | 24.2% | 23.1% | 22.7% | 22.9% | 22.4% | 20.2% | 22.3% | 20.8% | — | — |
| Other Income | Accelerating | 6 | 3 | 4 | 1 | 1 | 0 | 0 | 3 | — | — |
| Interest | Improving | 9 | 10 | 10 | 11 | 11 | 12 | 8 | 7 | — | — |
| Depreciation | Improving | 15 | 12 | 12 | 12 | 10 | 10 | 9 | 8 | — | — |
| Profit Before Tax | Strong Uptrend | 110 | 99 | 91 | 72 | 60 | 51 | 53 | 49 | — | — |
| Tax | Improving | 26 | 22 | 18 | 18 | 16 | 15 | 15 | 15 | — | — |
| Net Profit | Strong Uptrend | 85 | 77 | 73 | 54 | 43 | 36 | 38 | 34 | — | — |
| Net Margin | Improving | 15.9% | 14.9% | 15.3% | 13.1% | 12.3% | 10.1% | 12.2% | 11.7% | — | — |
Key Takeaways
- Consolidated revenue for Q1 FY2027 grew by 51.59% YoY to ₹5,343.38 million, driven by strong core pharmaceutical sales.
- Net Profit surged 95.79% YoY to ₹847.81 million, reflecting significant operating leverage and scale benefits.
- The quarter includes the first-time consolidation of Arinna Lifesciences Limited following an 85% stake acquisition completed on April 30, 2026.
- Subsequent to the quarter end, the company acquired a manufacturing facility in New Jersey, USA, for USD 2.9 million to expand its domestic US presence.
- R&D revenue expenditure remained high at ₹600.69 million for the quarter, emphasizing the company's research-focused growth strategy.
- Management successfully utilized ₹3,907.05 million of IPO proceeds to date, primarily for debt repayment and inorganic initiatives.
Management Guidance
Management is focusing on inorganic growth through strategic acquisitions and facility expansions in the US. The board has extended the timeline for utilizing remaining IPO proceeds to March 31, 2027, to ensure optimal capital allocation for strategic initiatives.
Sentiment Shift
Improving
The company has transitioned from a loss-making research firm to a highly profitable commercial player with accelerating margin expansion and successfully integrated acquisitions.
Outlook
The outlook remains positive as Rubicon continues to scale its US specialty portfolio and integrate new domestic manufacturing capabilities. The consolidation of Arinna Lifesciences is expected to contribute to diversified revenue streams.
From the Annual Report (Key Quotes)
“Results for current quarter ended June 30, 2026 includes results of Arinna Lifesciences Limited from the date of acquisition... hence the results for current quarter are not comparable with the previous periods.”
“AdvaGen Holdings’ Inc., a wholly owned subsidiary acquired a manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC.”
“The timeline for utilisation of the unutilised IPO proceeds has been extended up to March 31, 2027.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Rubicon Research Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.